Cargando…

Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study

BACKGROUND: Acquired thrombotic thrombocytopenic Purpura (aTTP) is a life-threatening ultra-orphan disease with a reported annual incidence between 1.5 and 6.0 cases per million in Europe and mainly affecting otherwise young and healthy adults aged 40 years on average. The goal of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Miesbach, Wolfgang, Menne, Jan, Bommer, Martin, Schönermarck, Ulf, Feldkamp, Thorsten, Nitschke, Martin, Westhoff, Timm H., Seibert, Felix S., Woitas, Rainer, Sousa, Rui, Wolf, Michael, Walzer, Stefan, Schwander, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858672/
https://www.ncbi.nlm.nih.gov/pubmed/31730475
http://dx.doi.org/10.1186/s13023-019-1240-0
_version_ 1783471000568987648
author Miesbach, Wolfgang
Menne, Jan
Bommer, Martin
Schönermarck, Ulf
Feldkamp, Thorsten
Nitschke, Martin
Westhoff, Timm H.
Seibert, Felix S.
Woitas, Rainer
Sousa, Rui
Wolf, Michael
Walzer, Stefan
Schwander, Björn
author_facet Miesbach, Wolfgang
Menne, Jan
Bommer, Martin
Schönermarck, Ulf
Feldkamp, Thorsten
Nitschke, Martin
Westhoff, Timm H.
Seibert, Felix S.
Woitas, Rainer
Sousa, Rui
Wolf, Michael
Walzer, Stefan
Schwander, Björn
author_sort Miesbach, Wolfgang
collection PubMed
description BACKGROUND: Acquired thrombotic thrombocytopenic Purpura (aTTP) is a life-threatening ultra-orphan disease with a reported annual incidence between 1.5 and 6.0 cases per million in Europe and mainly affecting otherwise young and healthy adults aged 40 years on average. The goal of this study was to assess the incidence of aTTP in Germany. METHODS: A systematic review was performed to determine the published evidence on the aTTP epidemiology in Germany. To obtain additional evidence on the proportion of aTTP cases within the national Thrombotic Microangiopathy (TMA) population a hospital-level study was performed, using a retrospective data collection approach. Diagnosis of aTTP was confirmed if ADAMTS13 level were < 10% and/or the medical records explicitly mentioned aTTP diagnosis. The aggregated hospital data were then projected to the national level using logistic regression techniques. RESULTS: The systematic literature search did not provide incidence estimates of aTTP in Germany. Eight centers (≈27% of the top 30 TMA hospitals) delivered data according to a predefined data collection form. On average (year 2014–2016) a total number of 172 aTTP episodes per year was projected (95% confidence interval [95%CI]: 132–212). The majority were newly diagnosed aTTP cases (n = 121; 95%CI: 105–129), and 51 were recurrent aTTP cases (95%CI: 27–84). The average annual projected incidence (year 2014–2016) of aTTP episodes was 2.10 per million inhabitants in Germany (95%CI: 1.60–2.58). CONCLUSIONS: The determined annual incidence of newly diagnosed aTTP cases and the overall annual incidence of aTTP episodes in Germany confirm the ultra-orphan character of aTTP. An external validation against international registries (France, UK and USA) shows that our findings are quite comparable with those international incidence rates.
format Online
Article
Text
id pubmed-6858672
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68586722019-11-29 Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study Miesbach, Wolfgang Menne, Jan Bommer, Martin Schönermarck, Ulf Feldkamp, Thorsten Nitschke, Martin Westhoff, Timm H. Seibert, Felix S. Woitas, Rainer Sousa, Rui Wolf, Michael Walzer, Stefan Schwander, Björn Orphanet J Rare Dis Research BACKGROUND: Acquired thrombotic thrombocytopenic Purpura (aTTP) is a life-threatening ultra-orphan disease with a reported annual incidence between 1.5 and 6.0 cases per million in Europe and mainly affecting otherwise young and healthy adults aged 40 years on average. The goal of this study was to assess the incidence of aTTP in Germany. METHODS: A systematic review was performed to determine the published evidence on the aTTP epidemiology in Germany. To obtain additional evidence on the proportion of aTTP cases within the national Thrombotic Microangiopathy (TMA) population a hospital-level study was performed, using a retrospective data collection approach. Diagnosis of aTTP was confirmed if ADAMTS13 level were < 10% and/or the medical records explicitly mentioned aTTP diagnosis. The aggregated hospital data were then projected to the national level using logistic regression techniques. RESULTS: The systematic literature search did not provide incidence estimates of aTTP in Germany. Eight centers (≈27% of the top 30 TMA hospitals) delivered data according to a predefined data collection form. On average (year 2014–2016) a total number of 172 aTTP episodes per year was projected (95% confidence interval [95%CI]: 132–212). The majority were newly diagnosed aTTP cases (n = 121; 95%CI: 105–129), and 51 were recurrent aTTP cases (95%CI: 27–84). The average annual projected incidence (year 2014–2016) of aTTP episodes was 2.10 per million inhabitants in Germany (95%CI: 1.60–2.58). CONCLUSIONS: The determined annual incidence of newly diagnosed aTTP cases and the overall annual incidence of aTTP episodes in Germany confirm the ultra-orphan character of aTTP. An external validation against international registries (France, UK and USA) shows that our findings are quite comparable with those international incidence rates. BioMed Central 2019-11-15 /pmc/articles/PMC6858672/ /pubmed/31730475 http://dx.doi.org/10.1186/s13023-019-1240-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Miesbach, Wolfgang
Menne, Jan
Bommer, Martin
Schönermarck, Ulf
Feldkamp, Thorsten
Nitschke, Martin
Westhoff, Timm H.
Seibert, Felix S.
Woitas, Rainer
Sousa, Rui
Wolf, Michael
Walzer, Stefan
Schwander, Björn
Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
title Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
title_full Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
title_fullStr Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
title_full_unstemmed Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
title_short Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
title_sort incidence of acquired thrombotic thrombocytopenic purpura in germany: a hospital level study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858672/
https://www.ncbi.nlm.nih.gov/pubmed/31730475
http://dx.doi.org/10.1186/s13023-019-1240-0
work_keys_str_mv AT miesbachwolfgang incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT mennejan incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT bommermartin incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT schonermarckulf incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT feldkampthorsten incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT nitschkemartin incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT westhofftimmh incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT seibertfelixs incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT woitasrainer incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT sousarui incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT wolfmichael incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT walzerstefan incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy
AT schwanderbjorn incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy